Literature DB >> 11731353

Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London.

P J Duke1, C Pantelis, M A McPhillips, T R Barnes.   

Abstract

BACKGROUND: Few epidemiological studies have assessed the extent and nature of comorbid non-alcohol substance misuse in people with schizophrenia in the community in the UK. AIMS: To study the extent and nature of comorbid non-alcohol substance misuse in people with schizophrenia in central London.
METHOD: Subjects were identified in an epidemiological census survey of South Westminster. Standardised assessment of each subject included demographic data, ratings of mental state and movement disorder and questioning about drug and alcohol misuse.
RESULTS: Individuals with schizophrenia or related psychoses were identified (n=352) and 57 (16%) reported a lifetime history of non-alcohol substance misuse. Age and gender were the main variables relevant to the extent and pattern of misuse. Self-reported non-alcohol substance misuse showed no significant relationship with a range of outcome measures.
CONCLUSIONS: The high proportion of subjects reporting non-alcohol substance misuse is comparable with figures from the USA. The reports of lifetime misuse most commonly referred to cannabis, psychostimulants, LSD, opiates and anticholinergics. Misuse was concentrated in those younger than 36 years and was reported more often by males.

Entities:  

Mesh:

Year:  2001        PMID: 11731353     DOI: 10.1192/bjp.179.6.509

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  18 in total

1.  Concurrent substance-related disorders and mental illness: the North American experience.

Authors:  Nady el-Guebaly
Journal:  World Psychiatry       Date:  2004-10       Impact factor: 49.548

Review 2.  Variations in rates of comorbid substance use in psychosis between mental health settings and geographical areas in the UK. A systematic review.

Authors:  Giuseppe Carrà; Sonia Johnson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-11-13       Impact factor: 4.328

3.  [The CIMH track concept in the treatment of psychotic disorders].

Authors:  Dusan Hirjak; Peter Gass; Michael Deuschle; F Markus Leweke; Andreas Böhringer; Nadine Schenkel; Doris Borgwedel; Marco Heser; Antje Breisacher; Andreas Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2020-03       Impact factor: 1.214

Review 4.  The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia.

Authors:  John H Krystal; D Cyril D'Souza; Jürgen Gallinat; Naomi Driesen; Anissa Abi-Dargham; Ismene Petrakis; Andreas Heinz; Godfrey Pearlson
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

Review 5.  Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?

Authors:  Nadia Solowij; Patricia T Michie
Journal:  J Psychiatry Neurosci       Date:  2007-01       Impact factor: 6.186

6.  [Prevalence of psychosis/substance abuse comorbidity. Clinical-epidemiological findings from different treatment settings in a large German city].

Authors:  T Schnell; K Neisius; J Daumann; E Gouzoulis-Mayfrank
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

7.  Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia.

Authors:  Thomas Wobrock; Helmut Sittinger; Bernd Behrendt; Roberto D'Amelio; Peter Falkai; Dieter Caspari
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-11-25       Impact factor: 5.270

8.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

9.  The role of cannabis in cognitive functioning of patients with schizophrenia.

Authors:  Thomas Schnell; Dagmar Koethe; Jörg Daumann; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2009-03-27       Impact factor: 4.530

10.  Sex difference in age of onset of schizophrenia: findings from a community-based study in India.

Authors:  Basappa K Venkatesh; Jagadisha Thirthalli; Magadi N Naveen; Kengeri V Kishorekumar; Udupi Arunachala; Ganesan Venkatasubramanian; Doddaballapura K Subbakrishna; Bangalore N Gangadhar
Journal:  World Psychiatry       Date:  2008-10       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.